MK-677 (ibutamoren) is an oral, non-peptide drug that mimics ghrelin and stimulates the pituitary to release more growth hormone, raising IGF-1 levels for about a full day after a single dose. Human trials show it reliably increases IGF-1 and lean body mass, but they also show increased appetite, fluid retention and worsening blood sugar control — without clear improvements in strength or function. It is not FDA-approved and is best understood as an investigational compound with real trade-offs.
What Is MK-677?
MK-677, also called ibutamoren, was developed by Merck in the 1990s as a potential treatment for growth hormone deficiency, frailty in older adults, and recovery after hip fracture. Chemically, it is a small molecule, not a peptide. It is frequently discussed alongside peptides because it works on the same receptor as the growth hormone–releasing peptides (GHRPs) such as ipamorelin.
What made MK-677 attractive to researchers was its convenience: it is absorbed by mouth and has a long duration of action, so a single daily dose produces a sustained rise in growth hormone and IGF-1. Most peptide secretagogues, by contrast, must be injected.
How MK-677 Works
MK-677 activates the ghrelin receptor (GHSR-1a) in the pituitary and hypothalamus. Ghrelin is often called the "hunger hormone," but it also signals the pituitary to release growth hormone. The sequence looks like this:
- Oral absorption — the molecule is well absorbed and long-acting.
- Ghrelin receptor activation — it mimics ghrelin at pituitary and hypothalamic receptors.
- Amplified growth hormone pulses — the size of natural GH pulses increases, and the inhibitory tone of somatostatin is reduced.
- Sustained IGF-1 rise — the liver produces more IGF-1, which stays elevated with daily use.
- Hunger signaling — because it acts like ghrelin, it also increases appetite.
That last step is not a side issue. It is built into the mechanism. For more on the downstream hormone, see Understanding IGF-1: The Anabolic Growth Factor.
What the MK-677 Research Shows
MK-677 is unusual among compounds discussed in longevity circles because it has actually been tested in randomized human trials. The most informative was a two-year randomized, placebo-controlled study in healthy older adults published in the Annals of Internal Medicine in 2008. In that trial:
- IGF-1 levels rose into the range typical of young adults.
- Fat-free mass increased.
- Strength and physical function did not improve meaningfully.
- Fasting glucose rose and insulin sensitivity decreased.
- Appetite increased, and mild fluid retention and muscle aches were reported.
A separate trial in older adults recovering from hip fracture was stopped early, and a numerical excess of heart failure events was observed in the treated group. Smaller studies have shown increases in deep (slow-wave) and REM sleep, which is one reason people seek it out.
The Blood Sugar Problem
In my practice, the metabolic effects of MK-677 are the central concern. Growth hormone naturally opposes insulin; it raises blood glucose. A compound that keeps growth hormone and IGF-1 elevated around the clock can push fasting glucose and insulin resistance in the wrong direction. Add increased appetite, and the risk compounds.
This matters because a large share of adults already have insulin resistance or prediabetes without knowing it. For them, MK-677 could accelerate exactly the process we work hardest to prevent. If this applies to you, read Prediabetes Reversal: Evidence-Based Strategies first.
Who Asks About MK-677, and What I Recommend Instead
Patients typically ask about MK-677 for three reasons: better sleep, easier muscle gain, and "anti-aging" through higher growth hormone. Each goal has better-supported first steps:
- Sleep: evaluating sleep apnea, alcohol, timing of training and caffeine, and circadian habits — the largest natural growth hormone pulse occurs during deep sleep.
- Muscle: progressive resistance training, adequate protein, and checking for hormonal or nutritional deficiencies.
- Healthy aging: cardiometabolic risk reduction, which has far stronger outcome data than raising IGF-1.
When the growth hormone axis is genuinely the issue, there are options to discuss with stronger regulatory standing, including the FDA-approved GHRH analog tesamorelin for its labeled indication. The broader comparison of growth hormone–axis approaches is covered in CJC-1295 Plus Ipamorelin: The Growth Hormone Axis Explained.
Regulatory Status
MK-677 is not FDA-approved for any use. It has been studied only as an investigational drug (including, more recently, for pediatric growth hormone deficiency under a different development name). FDA placed it among bulk substances not to be used in compounding in 2023, and FDA's compounding advisory committee voted against adding it to the 503A bulks list in 2024. It is prohibited by the World Anti-Doping Agency. Products sold online are not regulated as medicines.
How We Evaluate the Growth Hormone Axis at Laeeq M.D.
At Laeeq M.D., a question about MK-677 becomes a broader evaluation: fasting glucose, HbA1c and fasting insulin, IGF-1, lipids, a complete metabolic panel, blood pressure and a review of sleep and training. That baseline often reveals that the most effective intervention is something other than a growth hormone secretagogue. When any hormonal therapy is considered, the choice and dosing are individualized and monitored with labs — never decided before an evaluation.
Sources
- Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial — Nass R, et al. Annals of Internal Medicine, 2008
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks — U.S. Food and Drug Administration, updated 2026
Book a Consultation
If you are considering MK-677 or another growth hormone–related therapy, a careful metabolic evaluation should come first. Dr. Laeeq offers 60-minute consultations, virtually or in person in Reston, VA, for patients in Virginia, Maryland, Florida, Texas, California, Pennsylvania and Tennessee. Book a consultation to review your labs and goals.
This article is for educational purposes and is not medical advice. Discuss any treatment with a licensed physician who knows your history.
Frequently asked questions
Written by Dr. Laeeq Ahmed Butt, M.D., MBA
Board-certified internist practicing peptide and longevity medicine in Reston, VA, with virtual care in seven states. About Dr. Laeeq